The company developed Curodont technology, a non-invasive, peptide-based approach to the treatment of early carious lesions. One of its key products, Curodont Repair Fluoride Plus, is currently being rolled out in the US, where Henry Schein is the exclusive distributor. Since the launch of Curodont Repair Fluoride Plus in the US in early 2024, the product has been used to treat approximately three million teeth, according to vVARDIS, and it is now in nearly 20% of general dental practices nationwide and among the fastest-growing dental products in the US.

Jeremy Honeth, partner at Apollo, said in a press release that Drs Haley and Goly Abivardi had pioneered “a new category in dental care”, backed by peer-reviewed clinical studies, and built vVARDIS into “a differentiated business”. He added: “Apollo’s investment supports the company’s continued expansion in key markets across the US and Europe, bringing this restorative therapy to more practices and patients worldwide.”

“Curodont fills a longstanding gap in dentistry: when prevention fails, dentists now have a quick, easy-to-use non-invasive treatment. The rapid adoption of Curodont reflects the urgency of that unmet need,” said Dr Haley Abivardi. “Apollo’s investment will strengthen our commercial foundation in the US and Europe and will enable us to scale this environmentally sustainable technology across markets,” she stated.

Dr Goly Abivardi emphasised: “Our mission is to bring a medical, science-driven approach to dentistry. Using peptide-containing formulations, our non-invasive technology is an innovative treatment designed to treat caries without drilling and without polymer materials. Apollo’s investment reinforces our leadership in generative dentistry and advances the future of oral science.”

The Apollo investment follows two earlier financing announcements last year. In February 2025, vVARDIS secured US$35 million from global healthcare investor OrbiMed to support growth initiatives, including the further commercialisation of Curodont. In July 2025, the company raised an additional US$50 million from OrbiMed.